Introduction {#s1}
============

Breast cancer associated proteins 1 and 2 (BRCA1, −2) regulate an efficient non-mutagenic pathway of chromosome break repair and are described as guardians of chromosomal integrity ([@bib84]). They initiate RAD51-mediated homologous recombination (HR) ([@bib17]; [@bib48]; [@bib68]; [@bib83]) and facilitate restart of stalled replication ([@bib2]; [@bib38]; [@bib66]). BRCA2 belongs to a ubiquitous family of Recombination Mediator Proteins (RMPs), which stimulate formation of recombinase filament on single-stranded (ss) DNA protected by ssDNA-binding proteins, like SSB and RPA ([@bib3]; [@bib16]; [@bib34]). The Partner and Localizer of BRCA2 (PALB2) protein was discovered as a protein forming a complex with BRCA2 and regulating BRCA2 activity ([@bib86]). Like BRCA proteins, PALB2 is an essential mammalian protein linked to a similar spectrum of cancers and Fanconi anemia ([@bib19]; [@bib56]; [@bib87]). The PALB2 C-terminal WD40 domain interacts with BRCA2 ([@bib51]; [@bib86]) while the N-terminus forms a complex with BRCA1 ([@bib90]; [@bib91]). The latter localizes at double-stranded DNA break (DSB) sites at earlier stage of repair, inhibiting an alternative pathway of non-homologous end joining and initiating homology-directed repair (HDR) through recruitment of PALB2/BRCA2/RAD51 ([@bib61]).

PALB2 is often described as the hub for a network of tumor suppressors ([@bib54]; [@bib78]). In addition to BRCA1 and −2 interactions, it contains a chromatin-association motif (ChAM) that interacts with histones H3 and H2B ([@bib7]). PALB2 binds MRG15 protein, a component of histone acetyltransferase-deacetylase complexes ([@bib24]; [@bib77]); RAD51 and its paralogs RAD51C, RAD51AP1 and XRCC3 ([@bib18]; [@bib53]); translesion DNA polymerase η (Polη) during recombination-associated DNA synthesis ([@bib11]); an oxidative stress response protein KEAP1 ([@bib41]); and RNF168 ubiquitin ligase ([@bib39]). PALB2 is ubiquitinylated in G1 phase of the cell cycle by KEAP1 and CUL3, leading to its degradation, and, thereby, restraining its activity in S/G2 ([@bib52]).

Furthermore, PALB2 is an RMP itself as it promotes the assembly of RAD51-ssDNA presynaptic nucleofilaments in the absence of BRCA2 in vitro ([@bib10]; [@bib18]). PALB2 recruits Polη to DSB sites and stimulates recombination-associated DNA synthesis by Polη ([@bib11]).

Apart from protein-protein interaction domains, BRCA1, −2 and PALB2 proteins also contain DNA binding domains (DBDs), the function of which is poorly understood ([@bib10]; [@bib18]; [@bib55]; [@bib58]). Recently, studies of BRCA1/BARD1 complex interaction with DNA and RAD51 led to the discovery of the BRCA1/BARD1 role in RAD51-mediated strand invasion and D-loop formation ([@bib93]). Most missense mutations in the BRCA2 DBD are pathogenic ([@bib22]; [@bib85]). Disruption of DNA binding in a BRCA2 truncation variant lacking the PALB2-binding motif leads to a significant HDR reduction ([@bib71]). However, deletion of the BRCA2 DBD has a negligible effect when interaction with PALB2 is preserved, highlighting the functional importance of the previously reported DNA-binding property of PALB2 ([@bib10]; [@bib18]). Two truncation fragments of PALB2, T1 (residues 1--200) and T3 (residues 372--561), bind DNA ([@bib10]). While the precise mechanism of DNA interaction and its functional role remain unknown, several reports indirectly support its importance in DNA repair. For example, PALB2 truncation of 500 amino acids situated between the BRCA1 and BRCA2 binding motifs and containing both DBDs does not support BRCA2 and RAD51 foci formation in cells during DNA damage ([@bib78]). Since both the BRCA1-binding N-terminal and the BRCA2-interacting WD40 C-terminal domains are retained in this mutant, the results points to the potential importance of DBDs in PALB2 function. The importance of DNA binding was demonstrated for other RMPs, including bacterial RecFOR ([@bib33]; [@bib47]; [@bib63]; [@bib65]; [@bib81]) and eukaryotic RAD52 ([@bib1]; [@bib67]).

In the current study, we identified a major DBD of PALB2 (N-DBD) and specific amino acids involved in DNA binding. Mutations of only four amino acids significantly reduce RAD51 foci formation and the efficiency of HDR in a model cell system. PALB2 N-DBD by itself stimulates RAD51 strand exchange reactions. Surprisingly, we found that the PALB2 N-DBD supports both forward and inverse strand exchange even in the absence of RAD51 and can use RNA as a substrate. Altogether, our data reveal a novel activity of PALB2 and highlight the importance of PALB2 DNA binding in chromosome maintenance.

Results {#s2}
=======

The DNA-binding mechanism of PALB2 and its function in DNA repair {#s2-1}
-----------------------------------------------------------------

### The major DNA-binding site of PALB2 is localized in the N-terminal domain (N-DBD) {#s2-1-1}

A functional significance of PALB2 interaction with DNA was suggested by several studies described above, including a deletion encompassing both DBDs, the T1 (1--200) and T3 (372--561) fragments ([@bib78]). However, this deletion also removed several protein interaction sites. In two published studies the T1 and T3 fragments displayed different DNA binding activities measured by gel shift assays, but the cause remains unclear ([@bib10]; [@bib18]). We used a quantitative fluorescence polarization (FP) method to investigate interaction of PALB2 fragments with ss- and dsDNA oligonucleotides of different lengths. Both T1 and T3 fragments and the fragment consisting of amino acids 1--573 (PB2-573 in text), which includes both the T1 and T3, were cloned and purified ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). T1 fragment alone interacts with all tested substrates with similar affinities as of PB2-573, while the T3 fragment has significantly lower affinity for DNA ([Figure 1](#fig1){ref-type="fig"}). For example, the apparent equilibrium dissociation constant of T1 binding to ss49 K~d(T1/ss49)~ is 4.0 ± 1.3 nM, of 573 fragment K~d(573/ss49)~ is 4.8 ± 0.4 nM, while that of the interaction of T3 with ss49 K~d(T3/ss49)~ is 484 ± 80 nM, which is likely an overestimation due to weak binding. Hill coefficient values are close to one, suggesting non-cooperative interactions. The only exception is T1 binding to 49 bp dsDNA, however, the binding of PB2-573 to the same substrate is not cooperative. The only difference between T1 and PB2-573 was observed at an elevated salt concentration of 250 mM NaCl, where the PB2-573 fragment retained partial DNA binding activity ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). In both cases, interactions were inhibited by in 500 mM NaCl. The T1 fragment will be referred to as N-DBD in the text below. Interestingly, N-DBD binds long ssDNA substrates with significantly higher affinity than short ones with K~d(T1/ss20) ~= 80 ± 8.5 nM for 20 nt ssDNA versus K~d(T1/ss49)~ = 4.0 ± 1.3 nM for ss49. This suggests an interaction with ssDNA through multiple binding sites, potentially formed by the PALB2 oligomerization, as previously described ([@bib13]; [@bib79]), or through interaction with multiple binding sites within a monomer (see below). Interaction with dsDNA was length-independent, suggesting that more rigid dsDNA interacts with a single site.

![Interaction of T1, T3 and PB2-573 fragments with ss- and dsDNA.\
(**A**) Domain structure of PALB2. The PALB2 truncations used in the present study are shown below by magenta, blue and dark grey lines. (**B--E**) Equilibrium binding of PALB2 fragments, including T1 (blue), T3 (dark grey) and PB2-573 (magenta), to 20 nt ssDNA (ss20) (**B**), 49 nt ssDNA (ss49) (**C**), 20 bp dsDNA (ds20) (**D**), and 49 bp dsDNA (ds49) (**E**) monitored by fluorescence anisotropy of FAM-labelled ssDNA (5 nM). Each data point is an average of six readings from two different experiments. Reactions were performed in assay buffer with 20 mM Tris-acetate pH 7.0, 100 mM NaCl, 5% glycerol, 10% DMSO in a 40 μL reaction volume.\
10.7554/eLife.44063.004Figure 1---source data 1.Table with Hill coefficients (n) and equilibrium dissociation constants (K~d~, nM) values for graphs in [Figure 1B--E](#fig1){ref-type="fig"}.](elife-44063-fig1){#fig1}

### Identification of DNA-binding residues {#s2-1-2}

Since PALB2 DNA binding is salt-dependent ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), we performed an alanine scanning mutagenesis of several clusters of positively charged amino acids to identify the DNA binding site in the N-DBD ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The main DNA-binding cluster is formed by amino acids R146, R147, K148, and K149. Alanine substitution at these residues reduced binding affinity to ss49 by two orders of magnitude with a change in an apparent K~d~ from 4.0 ± 1.3 nM to 316 ± 59 nM in the case of N-DBD and from 4.8 ± 0.4 nM to 187 ± 55 nM in the case of PB2-573 ([Figure 2](#fig2){ref-type="fig"}). DNA binding was moderately affected by mutations of two other clusters, including K45A/K50A, for which the K~d~ was increased to 28 ± 5.2 nM ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), and the triple mutant R170A/K174A/R175A with similar change in K~d~. From these experiments, we concluded that the main DNA binding site is formed by residues 146--149, with a potential minor contribution from other basic amino acids of the N-DBD.

![Mutation of DNA binding residues.\
Isotherms of fluorescence anisotropy of FAM-ss49 (5 nM) titrated by PALB2 T1 (blue, open circles) and PB2-573 (magenta, open triangles) fragments and their mutants: T1 146-RK/AA (filled blue circles), T1 146-RRKK/AAAA (crossed open blue circles), and 573 146-RRKK/AAAA (filled magenta triangles) under conditions identical to those in [Figure 1](#fig1){ref-type="fig"}.\
10.7554/eLife.44063.008Figure 2---source data 1.Table with Hill coefficients (n) and equilibrium dissociation constants (K~d~, nM) values.](elife-44063-fig2){#fig2}

### Impairment of DNA repair in cells with the PALB2 DNA-binding mutant {#s2-1-3}

The mutations described above were used to separate the DNA-binding function from other macromolecular interactions of PALB2 during DNA repair in HeLa cells. Positively charged residues 146--149 were mutated to alanines in the full-length PALB2 protein and the effect of these mutations was measured in two assays. First, we evaluated RAD51 foci formation in cells after gamma irradiation ([Figure 3A](#fig3){ref-type="fig"}). Endogenous PALB2 was depleted by siRNA and cells were transformed with either wild type PALB2 or the DNA-binding site mutant ([Figure 3C](#fig3){ref-type="fig"}). PALB2 depletion leads to a severe defect in RAD51 foci formation. WT PALB2 restores RAD51 foci formation, while the DNA-binding site PALB2 mutant restores only \~50% of RAD51 foci formation. Similar effect was observed for the time frames between 1 to 8 hr after DNA damage ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Therefore, mutagenesis of only four positively charged residues in PALB2 has a major effect on efficiency of RAD51 recruitment to DNA damage sites.

![Effect of a PALB2 DNA-binding site mutation on homologous recombination.\
(**A**) Representative immunofluorescence images of RAD51 foci in PALB2 knockdown HeLa cells complemented with the indicated YFP construct and synchronized in S/G2 by double thymidine block, as determined by cyclin A staining. (**B**) RAD51 foci quantification in control siRNA (blue), siPALB2 (red) and with siPALB2 with subsequent complementation by siRNA-resistant constructs YFP-PALB2 (magenta) and 146AAAA DNA-binding site mutant PALB2 (green) at 2 hr after irradiation. (**C**) Western blotting of the samples shown in (**B**) to monitor knockdown and complementation efficiency. (**D**) Quantification of the gene-targeting efficiency of siRNA PALB2 cells complemented with wild-type and 146AAAA siRNA-resistant constructs mClover positive/iRFP cells. (**E**) Western blotting of the samples shown in (**D**) to monitor knockdown and complementation efficiency. \*\*\*p\<0.001 and \*\*\*\*p\<0.0001.](elife-44063-fig3){#fig3}

Similarly, we tested the role of PALB2 interaction with DNA for the efficiency of HDR in U2OS cells using a novel LMNA-Clover based assay, where DNA breaks at a specific gene are introduced by the CRISPR-Cas9 system ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) ([@bib12]). As in case of RAD51 foci formation, complementation of PALB2-depleted cells with the DNA-binding PALB2 mutant restores only 50% of HDR efficiency, in contrast to WT PALB2, which restores more than 90% of activity ([Figure 3D](#fig3){ref-type="fig"}). The N-DBD fragment also possesses a RAD51 interaction site, which can be potentially affected by mutations. We verified that the 146AAAA mutant interacts with RAD51 similarly to wild type PALB2 ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Therefore, the cellular effect of the 146AAAA mutant is defined exclusively by the inability of PALB2 to interact with DNA. Altogether, these studies show that PALB2 DNA binding plays a critical role in HR and DNA repair in vivo.

PALB2 promotes DNA and RNA strand exchange {#s2-2}
------------------------------------------

### PALB2 stimulates RAD51-mediated strand exchange and promotes a similar reaction without RAD51 {#s2-2-1}

PALB2 stimulates RAD51 filament formation even in the absence of BRCA2 ([@bib10]). Here, we investigated the ability of the PALB2 N-DBD to stimulate the strand exchange activity of RAD51 using a fluorescence-based strand exchange assay similar to the one previously published ([Figure 4A](#fig4){ref-type="fig"}) ([@bib28]; [@bib63]). Under solution conditions used in the DNA-binding assays in [Figure 1](#fig1){ref-type="fig"} and even with reduced NaCl concentration, RAD51 displayed a low activity, in contrast to *E. coli* RecA ([Figure 4](#fig4){ref-type="fig"}). RAD51 activity was stimulated by addition of 5 mM CaCl~2~ ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). RMPs stimulate recombinase activity even at unfavourable solution conditions, such as in the case of Rad52 ([@bib35]; [@bib49]), BRCA2 ([@bib28])([@bib37]; [@bib80]) and the Hop2-Mnd1 complex ([@bib15]). Similar to the previously published finding that the full length PALB2 stimulates RAD51 function ([@bib10]; [@bib18]), we found that the PALB2 N-DBD alone stimulates RAD51-mediated strand exchange ([Figure 4](#fig4){ref-type="fig"}).

![PALB2 promotes strand exchange between homologous DNA substrates.\
(**A**) Schematic representation of the strand exchange activity assay. ss90 (120 nM) was incubated with RecA (2 μM) or RAD51 (2 μM) for 5', then with PALB2 fragment (2 μM) for 5', then dsDNA (100 nM) was added and the Cy5 fluorescence was measured on a plate reader using 635 nm excitation and 680 nm emission wave-lengths. (**B**) Continuously measured Cy5 fluorescence after initiating reactions with RecA (blue), RAD51 (red), PALB2 N-DBD (magenta), RAD51 and PALB2 N-DBD (green), and without proteins (dark red). Each point is an average of three measurements. (**C**) Reaction products from (**B**) were deproteinized and separated on a native PAGE gel. Control in lane one represent Cy5-labelled dsDNA without IOWA quencher and in lane 2 Cy5-labelled ssDNA annealed with ss90. (**D**) Percentage of Cy5 fluorescence of the final reaction in (**B**).](elife-44063-fig4){#fig4}

Surprisingly, the N-DBD promotes strand exchange at a comparable rate even without RAD51. Reaction products were further analysed by EMSA gel shift to rule out an artefact of protein-specific fluorophore quenching ([Figure 4C](#fig4){ref-type="fig"}). The results were confirmed using DNA with different fluorescent labels ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). The strand exchange activity of N-DBD was even more efficient with longer dsDNA substrates ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). The reaction does not require ATP, resembling those promoted by RAD52 ([@bib43]). The strand exchange activity was not observed by full length PALB2 in previous publications ([@bib10]; [@bib18]). This difference could be due to significantly lower concentrations of PALB2 used in the referred studies as well as different experimental conditions. Currently, the low solubility of the full-length protein prevents recapitulation of assays in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} at comparable concentrations.

![The PALB2 N-DBD stimulates RAD51 strand exchange.\
(**A**) Dependence of the strand exchange activity on N-DBD concentration: 0.5 μM (black), 1 μM (brown), 2 μM (navy) and 4 μM (dark red). (**B**) A reaction similar to (**A**) in the presence of RAD51 (2 μM, red: without N-DBD). Each point is an average of three measurements in (**A**) and (**B**). (**C**) Deproteinated strand exchange activity products from (**A**) and (**B**) separated on native PAGE gel. (**D**) End-point values of the strand exchange reactions shown in (**A**) and (**B**) plotted against N-DBD concentration. Buffer and DNA concentration are identical to those in [Figure 4](#fig4){ref-type="fig"}.](elife-44063-fig5){#fig5}

![The plot of end points of strand exchange reactions with and without 0.5 μM RPA by (**A**) N-DBD and (**B**) N-DBD in the presence of 2 μM RAD51.\
Reactions are performed identically to those in [Figure 5](#fig5){ref-type="fig"}.](elife-44063-fig6){#fig6}

Since N-DBD stimulates a similar reaction on its own, it is unclear whether the N-DBD fragment stimulates RAD51 activity or if the two proteins function independently. In a limited titration experiment shown in [Figure 5](#fig5){ref-type="fig"}, the efficiency of the strand exchange increases proportionally to N-DBD concentration. In the presence of 2 μM of RAD51, the activity at T1 concentration of 0.5 μM increases four times and the maximum rate of strand exchange is reached at 1 μM of N-DBD. These data suggest a synergistic effect of two proteins in a strand exchange reaction. The DNA-binding mutant fragment (146AAAA) did not support strand exchange on its own and in the presence of RAD51 ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

Full length PALB2 promotes D-loop formation by RAD51 ([@bib10]; [@bib18]). However, we found that N-DBD did not support D-loop formation with ssDNA oligonucleotide and supercoiled dsDNA ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}).

### RPA inhibits PALB2-mediated strand exchange {#s2-2-2}

RPA inhibits formation of the presynaptic RAD51 filament on ssDNA and recombination mediator proteins RAD52 and BRCA2/DSS1 overcome this inhibitory effect ([@bib5]; [@bib28]; [@bib37]; [@bib49]; [@bib60]; [@bib70]; [@bib75]; [@bib76]; [@bib80]; [@bib92]). In both cases, the mediation reaction depends on protein interaction with RPA. PALB2 does not interact with RPA. Correspondingly, we found that RPA has a strong inhibitory effect on the strand exchange reaction by PALB2 DBD alone and in the presence of RAD51 ([Figure 6](#fig6){ref-type="fig"}).

### PALB2 stimulates an inverse strand exchange and can use an RNA substrate {#s2-2-3}

The strand exchange capability of PALB2 N-DBD resembles those of RAD52. RecA and Rad52 support an inverse strand exchange as well as R-loop formation ([@bib32]; [@bib43]; [@bib89]). Functional significance of this was demonstrated for an RNA-templated DSB repair ([@bib43]). Therefore, we tested the PALB2 N-DBD for similar activities. The PALB2 N-DBD supported both forward and inverse strand exchange with similar efficiencies ([Figure 7B,E](#fig7){ref-type="fig"}). Furthermore, PALB2 supported both reactions with a ssRNA substrate ([Figure 7C,F](#fig7){ref-type="fig"}). RAD52 was shown to have different efficiencies of forward and inverse reactions with relatively low forward and a more efficient inverse reactions ([@bib43]). We did not observe this difference with PALB2. The inverse strand exchange was slower than in case of RAD52 and comparable to that of RAD51 under optimal conditions. However, the substrates used in current work and in RAD52 studies are different.

![PALB2 promotes forward and inverse strand exchange with ssDNA and RNA substrates.\
Schematic representation of forward (**A**) and inverse (**D**) reactions. Cy5 fluorescence change for the forward reaction with ssDNA is shown in (**B**) and with RNA in (**E**) at different concentrations of T1 fragment ranging from 4 μM (brown in B, magenta in E) to 0.5 μM (blue) and without protein in orange. Similar time courses of inverse reactions for ssDNA are shown in (**C**) and for RNA in (**F**). Buffer and DNA concentration are identical to those in [Figure 4](#fig4){ref-type="fig"}. Each point is an average of three measurements.](elife-44063-fig7){#fig7}

### Mechanism of the PALB2 stimulated strand exchange {#s2-2-4}

To rule out a potential effect of DNA melting by PALB2, which may lead to nonspecific reannealing of a separated strands with complementary ssDNA in solution, the N-DBD was incubated with dsDNA without ssDNA ([Figure 8A](#fig8){ref-type="fig"}). The N-DBD does not melt dsDNA as there was no change in fluorescence of Cy5/Iowa-ds35 upon incubation with the protein in the absence of ssDNA, addition of which triggers the reaction. Moreover, N-DBD stimulates annealing of complementary ssDNA ([Figure 8B](#fig8){ref-type="fig"}). Therefore, the observed strand exchange is not a consequence of a nonspecific dsDNA melting by the protein.

![PALB2 does not unwind dsDNA and anneals complementary DNA strands.\
(**A**) Strand exchange reaction where Cy5/Iowa ds35 DNA (100 nM) was first incubated with three different concentrations of N-DBD for 30'. The complementary ss90 DNA (100 nM) was added at 30\' to initiate the strand exchange. (**B**) Annealing of Cy5- and Iowa-labelled complementary ss35 strands (100 nM) in the presence of different concentrations of PALB2 N-DBD. Buffers are identical to those in [Figure 4](#fig4){ref-type="fig"}.](elife-44063-fig8){#fig8}

Both RecA and RAD52 proteins, which support strand exchange, simultaneously interact with ds- and ssDNA through distinct binding sites located next to each other ([@bib1]; [@bib14]; [@bib26]; [@bib29]; [@bib42]; [@bib67]). PALB2 also interacts with both ss- and dsDNA ([Figure 1](#fig1){ref-type="fig"} and [@bib10]; [@bib18]), although the structure and the molecular details of PALB2 interaction with DNA remain unknown. To verify if other proteins characterized by comparable affinities to both ss- and dsDNA also support strand exchange, we tested prokaryotic RMPs, RecO and RecR. *E. coli* RecO alone stimulates strand annealing ([@bib31]; [@bib40]) and, in complex with RecR, stimulates RecA-mediated strand exchange with ssDNA bound to SSB ([@bib63]; [@bib81]; [@bib82]). Both RecO and RecOR interact with ss- and dsDNA ([@bib63]). However, neither RecO nor RecOR complex promote strand exchange in the absence of RecA ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Therefore, the simple ability of a protein to interact with ss- and dsDNA is not enough to promote strand exchange and even RMPs, which stimulate the reaction by RecA recombinase, do not support it in the absence of recombinase.

RecA/RAD51 and RAD52 proteins form oligomeric structures, such as recombinase-DNA filament ([@bib14]; [@bib20]; [@bib88]) or Rad52 ring structure ([@bib69]; [@bib73]). Both N-DBD ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}) and the full length PALB2 form oligomeric structures ([@bib13]; [@bib79]). The oligomerization is partially mediated by the N-terminal coiled-coil motif ([@bib79]). Thirty N-terminal amino acids form an antiparallel coiled-coil dimer ([@bib74]). However, gel filtration experiments suggest a tetrameric form ([Figure 8---figure supplement 2A](#fig8s2){ref-type="fig"}). The titration of double-labelled Cy5/Cy3 ssDNA performed similar to the experiment reported in [@bib21] revealed maximum FRET value at 1:4 or 1:5 ratio for both 70 nt and 40 nt long ssDNA ([Figure 8---figure supplement 2B](#fig8s2){ref-type="fig"}). The titration of ss49 by the N-DBD also suggests a stoichiometry of four or five N-DBD monomers per ss49 ([Figure 8---figure supplement 2C,D](#fig8s2){ref-type="fig"}). Importantly, the elution volume of the full length PALB2 in previous report also corresponds to a significantly higher molecular weight than that of a dimer, and the molecular weight of PALB2 with truncated coiled-coil domain higher than that of a monomer. Therefore, we expect to identify a secondary oligomerization site in N-DBD which should support a tetrameric structure.

Discussion {#s3}
==========

We identified major DNA-binding residues of PALB2 and demonstrated their critical role for HDR in cells. PALB2 is described as a scaffold protein linking BRCA1 with BRCA2 during HDR and interacting with many other chromatin proteins. However, the truncation variant with the preserved BRCA1 and BRCA2 binding motifs but without the middle portion of the protein, which contains DBDs, does not support BRCA2 and RAD51 recruitment to DSBs ([@bib78]). Recent studies suggest an alternative BRCA1-independent recruitment of PALB2 to DSB through direct interaction with RNF168 ([@bib39]; [@bib94]). However, this interaction is mediated by the C-terminal WD40 domain, which is preserved in the described above truncation mutant. A critical role of PALB2 DNA binding was also suggested by studies of the BRCA2 ([@bib71]), where the 'miniBRCA2' construct, including only DBDs with two BRC repeats, was 3--4 times less efficient than 'midiBRCA2' which includes PALB2 interaction motif. Moreover, interaction with PALB2 alleviates the requirement of BRCA2 DNA binding, including a deletion of the entire BRCA2 DBD. Here, we demonstrate that mutation of only four DNA-binding residues of PALB2 reduces both RAD51 foci and overall HDR efficiency by 50% in the presence of endogenous BRCA1 and BRCA2. Even at 8 hr post-IR siRNA PALB2 cells complemented with PALB2-146AAAA still display a defect in HR. We suggest that the mutant display a failure to repair a subset of DSBs due to its defective DNA binding. Therefore, PALB2 interaction with DNA is critical for recruitment of the BRCA2 and RAD51 to DSB sites and efficient DNA repair in cells.

Secondly, we demonstrate that the PALB2 N-DBD stimulates RAD51-mediated strand exchange in vitro. N-DBD encompasses the RAD51 binding site, therefore, it can recruit RAD51 to ssDNA to initiate nucleation of nucleoprotein filament. DNA-binding of N-DBD plays a critical role in this process, as the DNA-binding mutant (146AAAA) retains interaction with RAD51 ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}) but is unable to stimulate RAD51 binding to ssDNA ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Alternatively, the PALB2 N-DBD can support a DNA conformation favourable for RAD51 binding to ssDNA or/and nucleation of RAD51 filament, similarly to the prokaryotic RecOR proteins ([@bib4]; [@bib63]; [@bib65]).

The most unexpected finding is the ability of PALB2 to stimulate strand exchange between homologous ss- and dsDNA fragments in the absence of recombinase. This process is protein-specific and is not a consequence of simple DNA melting and reannealing of separated strands in solution, since the PALB2 N-DBD does not unwind the DNA helix and promotes DNA annealing. PALB2-mediated strand exchange differs from that of supported by RAD51, as it does not require ATP binding and hydrolysis and it is less efficient and not unidirectional. This reaction resembles that of the RAD52 ([@bib43]). In the cited manuscript, RAD52 promotes inverse reaction much more efficiently than forward and seemingly faster than that by PALB2 in our hands. However, the substrates used in RAD52 studies differ from those used in the current work by the presence of the ssDNA tail in dsDNA. The reaction with a no-tail substrate appears to be less efficient than the one supported by PALB2. Another distinction from RAD52 is the initial reaction rate, which was much faster in case of inverse reaction even with no-tail substrate for RAD52. PALB2-mediated reactions are slower with no difference between forward and inverse reactions.

Proteins supporting strand exchange, such as RecA and RAD52, share several common features. They interact with both ss- and dsDNA through distinct sites located next to each other, they form oligomeric structures, such as recombinase-DNA filament or Rad52 ring structure, and they distort the dsDNA helix to initiate strand exchange with the bound complementary ssDNA. RecA stretches dsDNA ([@bib14]; [@bib36]), while Rad52 bends the DNA helix bound to the toroidal oligomeric ring ([@bib9]). The PALB2 N-DBD interacts with both ss- and dsDNA. Previously, we demonstrated that PALB2 immobilized on ssDNA beads efficiently pulls down non-homologous dsDNA ([@bib10]). It is unclear whether ss- and dsDNA substrates are bound to the same sites of different subunits of a PALB2 oligomer or two different DNA binding sites on the same monomer. The presence of at least two other minor DNA-binding sites in the N-DBD suggests such a possibility. Higher affinity towards longer ssDNA ([Figure 1](#fig1){ref-type="fig"}) and the FRET experiment ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}) support a model of wrapping long flexible ssDNA around an oligomer. In contrast, interaction with dsDNA is less length dependent ([Figure 1](#fig1){ref-type="fig"}). We can speculate that binding of dsDNA to more than one monomer in PALB2 oligomer can trigger DNA helix distortion. Thus, PALB2 shares several specific structural and DNA-interaction features with both RecA/RAD51 and Rad52 proteins and supports a protein-specific strand exchange reaction. At the same time, PALB2 does not support D-loop formation with supercoiled dsDNA opposite to a full length PALB2. This may be a consequence of the inability to efficiently bind and distort supercoiled dsDNA plasmid through the secondary DNA-binding site.

It is important to note one distinct feature of the PALB2 N-DBD: the secondary structure prediction ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) suggests a different folding of the N-DBD fragment than that of RecA-like domains or a Rad52. The latter proteins are formed by α/β sandwich folds, while PALB2 N-DBD folding is predicted to be composed of only α-helices, which may form helical bundle-like structure similar to that of Hop2-Mnd1 ([@bib30]). Therefore, PALB2 N-DBD represents a novel structural fold that supports strand exchange.

While the functional significance of this property remains to be investigated, it further supports the involvement of PALB2 in specific DNA transactions during HDR, similar to the involvement of BRCA1/BARD1 in D-loop formation ([@bib93]). It was shown that both PALB2 and BRCA2 stimulate Polη DNA synthesis within a D-loop substrate in vitro through the recruitment of the polymerase to the invading strand in the D-loop ([@bib11]). Interestingly, DNA synthesis was more efficient in the presence of PALB2 than BRCA2, while both proteins were shown be equally efficient in recruiting polymerase to DSB sites. PALB2 strand exchange may contribute to other steps of HDR such as second-end capture ([@bib44]; [@bib45]; [@bib50]). Interestingly, PALB2 (FANCN) and BRCA2 (FANCD) are involved in replication-dependant removal of interstrand DNA crosslinks associated with Fanconi anemia ([@bib27]; [@bib46]; [@bib87]). The strand exchange function of PALB2 may also be important for alternative DNA repair pathways. Indeed, PALB2 supports strand exchange not only with ssDNA, but with ssRNA substrates, and can be involved in transcription-initiated DNA repair. This hypothesis seems particularly attractive in light of the PALB2 interaction with MRG15 and its localization at the sites of actively transcribed genes [@bib8]. 

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\            Designation                  Source or reference                                                  Identifiers    Additional information
  (species) or resource                                                                                                                     
  ------------------------ ---------------------------- -------------------------------------------------------------------- -------------- ------------------------------------------------------------------------
  Cell line (Human)        HeLa                         ATCC                                                                 CCL-2          

  Cell line (Human)        U2OS                         ATCC                                                                 HTB-96         

  Cell line (Human)        HEK293T                      ATCC                                                                 CRL-11268      

  Sequence-base\           siRNA sequences              This paper                                                                          [Supplementary file 1E](#supp1){ref-type="supplementary-material"}
  reagent                                                                                                                                   

  Sequence-base\           oligonucleotide\             This paper                                                                          [Supplementary file 1C](#supp1){ref-type="supplementary-material"}
  reagent                  JYM1413                                                                                                          

  Chemical\                Lipofectamine\               Invitrogen                                                           13778--150     
  compound, drug           RNAiMAX                                                                                                          

  Chemical\                Thymidine                    Sigma                                                                T1895-1G       
  compound, drug                                                                                                                            

  Chemical\                Lipofectamine 2000           Invitrogen                                                           11668019       
  compound, drug                                                                                                                            

  Chemical\                Proteinase K                 Sigma                                                                P2308-100MG    
  compound, drug                                                                                                                            

  Chemical\                \[gamma-32P\] ATP            Perkin Elmer                                                         NEG502A250UC   
  compound, drug                                                                                                                            

  Recombinant\             YFP-CTL or YFP\              [@bib57]                                                                            
  DNA reagent              (plasmid)                                                                                                        

  Recombinant\             YFP-PALB2 (plasmid)          [@bib57]                                                                            
  DNA reagent                                                                                                                               

  Recombinant\             YFP-PALB2\                   This paper                                                                          [Supplementary file 1B](#supp1){ref-type="supplementary-material"}
  DNA reagent              146AAAA (plasmid)                                                                                                

  Recombinant\             pCR2.1-mClover-\             [@bib59]                                                                            
  DNA reagent              LMNAdonor (plasmid)                                                                                              

  Recombinant\             pX330-LMNAgRNA\              [@bib59]                                                                            
  DNA reagent              (plasmid)                                                                                                        

  Recombinant\             iRFP670 (plasmid)            [@bib59]                                                                            
  DNA reagent                                                                                                                               

  Recombinant\             FLAG vector (plasmid)        [@bib57]                                                                            
  DNA reagent                                                                                                                               

  Recombinant\             FLAG-PALB2 (plasmid)         [@bib57]                                                                            
  DNA reagent                                                                                                                               

  Recombinant\             FLAG-PALB2\                  This paper                                                                          [Supplementary file 1B](#supp1){ref-type="supplementary-material"}
  DNA reagent              146AAAA (plasmid)                                                                                                

  Recombinant\             pPB4.3                       PMID:[15899844](https://www.ncbi.nlm.nih.gov/pubmed/15899844)                       
  DNA reagent                                                                                                                               

  Other                    DAPI stain                   Invitrogen                                                           D1306          (1 µg/mL)

  Commercial\              SE Cell Line\                VWR                                                                  CA10064-148    
  assay, kit               4D-Nucleofector X Kit                                                                                            

  Antibody                 anti-RAD51\                  Novus Biologicals                                                    NB100-148      (1:1000)
                           (mouse monoclonal)                                                                                               

  Antibody                 anti-GFP\                    Roche                                                                11814460001    (1:1000)
                           (mouse monolconal)                                                                                               

  Antibody                 RAD51\                       B-Bridge International                                               70--001        (1:7000)
                           (rabbit polyclonall)                                                                                             

  Antibody                 cyclin A\                    BD Biosciences                                                       611268         (1:400)
                           (mouse monoclonal)                                                                                               

  Antibody                 Alexa Fluor 568\             Molecular Probe                                                      A11011         (1:10000)
                           goat anti-rabbit                                                                                                 

  Antibody                 Alexa Fluor 647\             Molecular Probe                                                      A21235         (1:10000)
                           got anti-mouse                                                                                                   

  Software,\               Prism                        GraphPad                                                             Ver-6          
  algorithm                                                                                                                                 

  Software,\               Volocity                     Quorum Technologies                                                  v6.0.1         
  algorithm                                                                                                                                 

  Sequence-base\           cloning primers,\            IDT, Technology                                                                     [Supplementary file 1B,C,D](#supp1){ref-type="supplementary-material"}
  reagent                  DNA-binding substrates,\                                                                                         
                           FRET substrates                                                                                                  

  Strain, Strain\          BL21-star cells              ThermoFisher Scientific                                              C601003        
  background (*E. Coli*)                                                                                                                    

  Strain, Strain\          OmniMAX cells                ThermoFisher Scientific                                              C8540-03       
  background (*E. Coli*)                                                                                                                    

  Recombinant\             pSMT3-PALB2-T1               This paper                                                                          
  DNA reagent                                                                                                                               

  Recombinant\             pSMT3-PALB2-T3               This paper                                                                          
  DNA reagent                                                                                                                               

  Recombinant\             pSMT3-PALB2-573              This paper                                                                          
  DNA reagent                                                                                                                               

  Other                    His60 Ni Superflow           Clonetech                                                            635660         

  Other                    Heparin 5 ml\                GE Heathcare\                                                        17040701       
                           HiTrap column                Lifesciences                                                                        

  Other                    Superdex-200\                GE Heathcare\                                                        17517501       
                           10/300 GL column             Lifesciences                                                                        

  Recombinant\             pET11-Rad51                  Dr. A Mazin\                                                                        
  DNA reagent                                           Lab; PMID:[11751636](https://www.ncbi.nlm.nih.gov/pubmed/11751636)                  

  Recombinant\             pSMT3-RAD51                  This paper                                                                          
  DNA reagent                                                                                                                               

  Recombinant\             p11d-tRPA                    AddGene,\                                                            102613         
  DNA reagent                                           [@bib25]                                                                            

  Other                    Affi-Gel blue affinity gel   BioRad                                                               1537301        

  Instrument               Synergy four plate reader    BioTek                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein purification {#s4-1}
--------------------

### PALB2 truncations {#s4-1-1}

PALB2 N-terminal fragments PALB2-T1 (1--200 aa) and PALB2-573 (1--573 aa) were cloned into pET28b + based pSMT3 vector (provided by Dr. R.A. Kovall, University of Cincinnati) containing the N-terminal 6xHis-SUMO tag using *Sal*I and *Nde*I cloning sites. pSMT3-PALB2 T1, pSMT3-PALB2 573 were transformed into BL21\* cells. Cell cultures were grown in LB to OD600 = 0.7 and protein expression was induced by adding 0.2 mM IPTG and carried out at 16°C overnight. Cells were lysed with lysozyme (0.25 mg/mL at RT for 30 min) in lysis buffer (25 mM HEPES pH 8.0, 1 M NaCl, 10% glycerol, 0.3% Brij35, 1 mM TCEP, 2 mM CHAPS and 1 mM PMSF), followed by three rounds of sonication (50% output and 50% pulsar settings for 4 min). Cell debris were removed by centrifugation at 30,600 x g for 45 min. Supernatant was loaded on a NiNTA column (5 ml) equilibrated with binding buffer (25 mM HEPES pH 8.0, 1 M NaCl, 10% glycerol, 1 mM TCEP, 2 mM CHAPS and 10 mM imidazole). NiNTA beads were washed with binding buffer and the protein was eluted with binding buffer supplemented with the same buffer adjusted to 250 mM imidazole. The SUMO tag was cleaved with Ulp1 protease while dialyzing against buffer without imidazole (25 mM HEPES pH 8.0, 1 M NaCl, 10% glycerol, 1 mM TCEP and 2 mM CHAPS) overnight and the protein was purified with a second NiNTA column. The protein was diluted 10X by binding buffer without NaCl to the final NaCl concentration of 100 mM, loaded to a Hi-Trap heparin affinity column (5 ml, GE health sciences) and eluted with a gradient of NaCl (100 mM to 1000 mM). Protein eluted from the heparin column at \~500 mM NaCl concentration. Protein fractions were dialysed against storage buffer (25 mM HEPES pH 8.0, 300 mM NaCl, 40% glycerol, 1 mM TCEP and 2 mM CHAPS) overnight, aliquoted and stored at −80°C.

PALB2 T3 fragment was purified as described in [@bib10].

### RAD51 purification {#s4-1-2}

We used two expression constructs and purification protocols. (1) Human RAD51 protein was purified from the pET11-Rad51 vector (gift from Dr A. Mazin) according to the published protocol ([@bib72]). The protein was induced at 37°C for 3 hr by supplementing LB media with 0.5 mM IPTG. Cells were suspended in 25 mM Tris-HCl pH8.0, 1 M urea, 1 M NaCl, 5 mM DTT, 0.3% Brij35% and 10% glycerol. Cells were lysed with lysozyme (0.25 mg/mL at RT for 30 min) followed by three rounds of sonication (50% output and 50% pulsar settings for 1 min). 24 mg/ml ammonium sulfate was gradually added to the supernatant and equilibrated overnight at 4°C. Precipitates were centrifugation at 30,600 x g for 45 min. Pellets were solubilized in 30 ml of binding buffer (25 mM Tris-HCl pH8.0, 1 M NaCl, 5 mM DTT, 10% glycerol and 20 mM imidazole). Insoluble particles were removed by centrifugation at 30,600 x g for 40 min. The protein was bound to Ni NTA beads, extensively washed with binding buffer and eluted in binding buffer supplemented with 250 mM imidazole.

\(2\) Alternatively, human RAD51 gene was cloned into pSMT3 vector using *Sal*I and *Nde*I cloning sites. pSMT3-Rad51 protein expression was carried out at 16°C overnight by addition of 0.2 mM IPTG. SUMO tagged Rad51 protein was purified according to the steps described for the PALB2 fragments. Purified Rad51 protein was dialysed against storage buffer (25 mM HEPES pH 8.0, 300 mM NaCl, 40% glycerol, 1 mM TCEP and 2 mM CHAPS) overnight, aliquoted and stored in −80°C until further use. Proteins from both preparations had comparable properties. Data are shown for experiments performed with the second construct, except for [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.

*E. coli* RecA was purified exactly as described in [@bib23]. *E. coli* RecO and RecR proteins were purified as described ([@bib64]; [@bib62]). Protein concentration was determined by Bradford reagent (Thermo scientific).

Trimeric RPA complex was expressed using p11-tRPA vector (Addgene, plasmid \#102613) and purified accordingly to the published protocol ([@bib6]; [@bib25]). A fresh transformant of p11d-tRPA was grown to 0.5 OD at 37°C in a litre of LB media. Protein expression was induced by IPTG (0.2 mM) at 16°C overnight. Cells were harvested and suspended in lysis buffer (25 mM HEPES pH 8.0, 0.25 mM EDTA, 1 mM PMSF, 1 mM TCEP and 0.01% NP-40). Cells were lysed by incubation with lysozyme (0.25 mg/mL at 25°C for 30 min) and followed by sonication (50% output and 50% pulsar settings for 4 min). Cell debris were removed, and supernatant was loaded on an Affi-Gel Blue column (5 ml, Biorad) equilibrated with lysis buffer. The column was washed sequentially with five column volumes of lysis buffer containing 50 mM KCl, 0.8 M KCl, 0.5 M NaSCN and 1.5 M NaSCN. RPA elutes in the 1.5 M NaSCN wash. This fraction was diluted ten times to a final concentration of NaSCN to 150 mM and applied to heparin column. The column was washed with lysis buffer followed by elution with a linear gradient of NaCl (0.1--1M). The peak fractions were pooled, concentrated, flash frozen in liquid nitrogen and stored at −80°C until further use.

Site-directed mutagenesis {#s4-2}
-------------------------

Target amino acids were mutated by site directed mutagenesis using Stratagene QuikChange protocol. Single, double, triple and four residues mutants were generated by single stranded synthesis ([Supplementary file 1B](#supp1){ref-type="supplementary-material"}). PCR samples were subjected to *Dpn*I digestion at 37°C for 6 hr and annealed gradually by reducing temperature from 95°C to 37°C for an hour with a 1°C drop per minute. *Dpn*I treated PCR samples were transformed into chemically competent OmniMAX cells (ThermoFischer). Mutations were confirmed by sequencing and plasmids were transformed into BL21(DE) cells. Mutant proteins were expressed and purified exactly as described for wild type fragments.

DNA binding assay {#s4-3}
-----------------

Fluorescence anisotropy experiments were carried out at room temperature with 5 nM fluorescein (6FAM)-labelled DNA substrates ([Supplementary file 1C](#supp1){ref-type="supplementary-material"}) using a Synergy four plate reader (BioTek). Titration with protein was performed by serially diluting protein in 40 μL of assay buffer (20 mM Tris-acetate pH 7.0, 100 mM NaCl, 5% glycerol, 1 mM TCEP and 10% DMSO) from 5000 nM to 0.3 nM and incubating with DNA substrate for 15 min at RT. Fluorescence anisotropy was measured by excitation at 485/20 nm and by monitoring emission 528/20 nm at room temperature using Gen5.0 (BioTek) software. An equilibrium dissociation constant was calculated with Prism software using one to one binding scheme, $\left\lbrack P \right\rbrack + \left\lbrack D \right\rbrack = \left\lbrack DP \right\rbrack$, where D is DNA and P is PALB2. Anisotropy data were fitted by a non-linear regression analysis of Prism software using standard four-parameter logistic equation to identify K~d~$$y = y_{min} + \left( \frac{y_{max} - y_{min}}{1 + 10^{{({logEC50 - X})} \times n}} \right)$$

Where, $y_{min}$ and $y_{max}$ is the minimum and maximum anisotropy values, X represents the log concentration of protein, $n$ represents Hillslope, and EC50 is equal to K~D~. R^2^ is determined by the prism software by computing the sum of the squares of the distances of the points from the best-fit curve determined by nonlinear regression model.

DNA annealing assay {#s4-4}
-------------------

DNA annealing assays were performed with Cy5-labelled ss35 and compl IOWA-labelled ss35 (100 nM, [Supplementary file 1D](#supp1){ref-type="supplementary-material"}). The protein at 1, 2 and 4 μM concentrations was mixed and incubated with Cy5-labelled ssDNA for 5 min at 37°C in 40 μL reaction buffer (40 mM HEPES pH 7.5, 20 mM NaCl and 1 mM TCEP). Reactions were initiated by addition of compl IOWA-labelled ss35 (100 nM) in 40 μL of reaction buffer. Decrease in Cy5 fluorescence was monitored by measuring fluorescence at 680 nm by excitation at 635 nm on a Synergy four plate reader (BioTek).

Strand exchange fluorescent assay {#s4-5}
---------------------------------

DNA strand exchange assays (80 μl) were performed with 35 bp dsDNA obtained by annealing of 5'-Cy5- and 3'-IOWA-labelled compl strands ([Supplementary file 1D](#supp1){ref-type="supplementary-material"}) and a 90mer ssDNA (ss90) with a region homologous to the plus strand. Alternatively, FAM/Dabsyl 49 bp DNA was used. For the forward reaction, ss90 (100 nM) was incubated with 2 μM (or as mentioned in the figure legends) protein for 10 min in 40 μL reaction buffer (40 mM HEPES pH 7.5, 20 mM NaCl, 5 mM MgCl~2~, 1 mM TCEP and 0.02% Tween 20) at 37°C. Strand exchange was initiated by addition of 100 nM Cy5/IOWA-dsDNA35 (or FAM/Dabsyl-dsDNA49), the plate was immediately placed in plate reader and the intensity of Cy5 (or FAM) fluorescence was measured at 30 s intervals for 1 hr with excitation at 635 nm and emission at 680 nm. For reactions with RecA and Rad51, an ATP regeneration system (2 mM ATP, 3 mM phosphoenol pyruvate and 30 U of pyruvate kinase) was used (Sigma-Aldrich, USA). Experiments without RecA and RAD51 were performed without ATP. For the inverse reaction, protein was incubated with Cy5/IOWA-dsDNA35 (or FAM/Dabsyl-dsDNA49) substrate and reaction was initiated by addition of ss90. The strand exchange assay with ssRNA substrate was performed as described above using a 60 ribonucleotide RNA ([Supplementary file 1D](#supp1){ref-type="supplementary-material"}) compl to that of 35 bp DNA. Alternatively, Cy3- and Cy5-labelled DNA oligonucleotides were used to prepare dsDNA substrate and the products were analysed by EMSA PAGE (below).

EMSA PAGE {#s4-6}
---------

Fluorescent-labelled DNA products of strand exchange reactions were also analysed on EMSA PAGE. After fluorescence measurement on plate reader, the final reaction mix (80 μl) products were deproteinated by incubation with proteinase K (0.5 mg/ml) with 0.5 mM EDTA and 1% w/v SDS for 20 min at 37°C and the DNA fragments were separated on 10% PAGE gel in TBE buffer. The gel was imaged using a Typhoon 9400 image scanner (GE) and analysed with ImageJ software.

FRET assay {#s4-7}
----------

FRET assay was performed in 96 well plate format. 100 nM of dual labelled dT~70~ or ss40 (Cy5 at 5' end and Cy3 at 3' end) was dispensed into 80 μL assay buffer identical to the buffer in the strand exchange assay ([Supplementary file 1D](#supp1){ref-type="supplementary-material"}). Excitation was at 540/25 nm bandpass. Emission for both Cy3 at 590/35 nm bandpass and Cy5 at 680/30 nm were measured. PALB2 was added with final concentration between 4000 and 15.6 nM and incubated for 10 min. FRET efficiency was calculated by using the formula $FRET = \frac{1.51 \times Icy5}{\left( {1.51 \times Icy5 + 0.669 \times Icy3} \right)}$, where 1.51 and 0.669 are correction factors for fraction of Cy5 and Cy3 intensities in Cy3 and Cy5 channels respectively. Protein concentrations were as described in the figure legends.

D-loop assay {#s4-8}
------------

D-loop buffer (25 mM Tris-acetate pH 7.5, 100 µg/mL bovine serum albumin, 2 mM CaCl~2~, 2 mM ATP, 1 mM DTT), containing 1 µM of radiolabelled oligonucleotide JYM1413 (homologous sequence to the plasmid pPB4.3, [Supplementary file 1C](#supp1){ref-type="supplementary-material"}) was incubated for 5 min at 37°C with the indicated concentration of RAD51 or PALB2-T1 fragment. CsCl- purified pPB4.3 replicative form I DNA (300 µM) was added and the reaction and incubated for 5 min. Finally, the reaction was stopped with the addition of 0,6% SDS, 20 mM Tris-HCl pH 7.5, 20 mM MgCl~2~ and 2 mg/mL proteinase K following by incubation for 30 min at 37°C. Labelled DNA products were analysed by electrophoresis through a 0.8% TAE1X/agarose gel, ran at 65V for 1 hr, dried onto DE81 filter paper at 85°C, and visualized by autoradiography.

RAD51 foci assay {#s4-9}
----------------

HeLa cells were seeded on glass coverslips in 6-well plates at 225 000 cells per well. Knockdown of PALB2 was performed 18 hr later with 50 nM PALB2 siRNA ([Supplementary file 1E](#supp1){ref-type="supplementary-material"}) using Lipofectamine RNAiMAX (Invitrogen). After 5 hr, cells were subjected to double thymidine block. Briefly, cells were treated with 2 mM thymidine for 18 hr and released after changing the media.

After a release of 9 hr, PALB2 silenced cells were complemented using transfection with the indicated YFP constructs using Lipofectamine 2000. Cells were then treated with 2 mM thymidine for 17 hr and protected from light from this point on. After 2 hr of release from the second block, cells were X-irradiated with 2 Gy and processed for immunofluorescence 1 hr, 2 hr, 4 hr, 6 hr and 8 hr post-irradiation. All immunofluorescence dilutions were prepared in PBS and incubations performed at room temperature with intervening washes in PBS. Cell fixation was carried out by incubation with 4% paraformaldehyde for 10 min followed by 100% ice-cold methanol for 5 min at −20°C. Cells were then permeabilized in 0.2% Triton X-100 for 5 min and quenched using 0.1% sodium borohydride for 5 min. After blocking for 1 hr in a solution containing 10% goat serum and 1% BSA, cells were incubated for 1 hr with primary antibodies to RAD51 (B-bridge International, \#70--001) and to cyclin A (BD Biosciences, \# 611268) diluted in 1% BSA. Secondary antibodies, Alexa Fluor 568 goat anti-rabbit (Invitrogen, \#A-11011) and Alexa Fluor 647 goat anti-mouse (Invitrogen, \#A-21235), were used in PBS containing 1% BSA for 1 hr. Nuclei were stained for 10 min with 1 μg/mL 4, 6-diamidino-2-phenylindole (DAPI) prior to mounting onto slides with 90% glycerol containing 1 mg/ml paraphenylenediamine anti-fade reagent. Z-stack images were acquired at 63X magnification on a Leica DM6000 microscope, then deconvoluted and analysed for RAD51 foci formation with Volocity software v6.0.1 (Perkin-Elmer Improvision). The number of RAD51 foci per cyclin A-positive cells (n = 300), among the transfected population, was manually scored and reported in a scatter dot plot representing the SEM. An Anova test (Kruskal-Wallis-test for multiple comparison) was performed followed by a non-parametric Mann-Whitney test.

CRISPR-Cas9/mClover-LMNA1 mediated HR assay ([@bib59]) {#s4-10}
------------------------------------------------------

U2OS cells were seeded in 6-well plates. Knockdown of PALB2 ([@bib12]) was performed 6--8 hr later using Lipofectamine RNAiMAX (Invitrogen). Twenty-four hours post-transfection, 1.5−2 × 10^6^ cells were pelleted for each condition and resuspended in 100 μL complete nucleofector solution (SE Cell Line 4D-Nucleofector X Kit, Lonza) to which 1 μg of pCR2.1-mClover-LMNAdonor, 1 μg pX330-LMNAgRNA, 0.1 μg of iRFP670 and 1 μg of pcDNA3 empty vector or the Flag-PALB2 constructs, and 20 nM of each siRNA were added. Once transferred to a 100 μl Lonza certified cuvette, cells were transfected using the 4D-Nucleofector X-unit, program CM-104 and transferred to a 10 cm dish. After 48 hr, cells were trypsinized and plated onto glass coverslips. Expression of the mClover was assayed the next day by fluorescence microscopy (63X), that is 72 hr post-nucleofection. Data are represented as mean percentages of mClover-positive cells over the iRFP-positive population from five independent experiments (total n \> 100 iRFP-positive cells) and reported in a scatter dot plot representing SEM, and a classical one-way Anova test was performed.

GFP-Trap pulldown {#s4-11}
-----------------

HEK293T were plated to 80% confluency and transfected with YFP-CTL, YFP-PALB2 or YFP-PALB2-146AAAA vector using Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific). 24 hr after, cells were irradiated with 5 Gy and processed for GFP-Trap Pulldown 2 hr post-irradiation. Briefly, cells were washed twice with ice cold PBS and lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0,5% NP40, containing PMSF, Aprotinin, Leupeptin, NaF, and Na~2~VO~4~). Lysates were sonicated (three times 10 s at 30% amplitude on ice) and centrifuged at 16000 g, for 30 min at 4°C. Protein lysates (3 mg) were incubated with GFP-Trap beads (Chromotek) for 1 hr at 4°C. Beads were washed three times with lysis buffer (without NP40) and bound proteins were resuspended in 35 µL of Laemmli SDS-sample buffer and heated to 95°C for 10 min.

Samples were run on NuPAGE 4--12% bis-Tris Protein Gels (Invitrogen) in NuPAGE MOPS SDS Running Buffer according to the manufacturer's protocol and transferred to Nitrocellulose membrane (Amersham) using XCell II Blot Module (Invitrogen) in 20% methanol transfer buffer. Immunoblots were performed using the following antibodies: anti-RAD51(14B4) (Novus Biologicals, \#NB100-148) and anti-GFP (Roche, \#11814460001).

Plasmids and siRNA {#s4-12}
------------------

peYFP-C1-PALB2 was modified to be resistant to PALB2 siRNA by Q5 Site-Directed Mutagenesis Kit (NEB, E0554) using primers JYM3892/3893 ([Supplementary file 1E](#supp1){ref-type="supplementary-material"}). The resulting siRNA-resistant construct was then used as a template to generate the mutant construct YFP-PALB2 146AAAA with the primers JYM3909/JYM3910. Flag-tagged PALB2 146AAAA mutant was also obtained via site-directed mutagenesis on pcDNA3-Flag PALB2 ([@bib57]).

Cell lines {#s4-13}
----------

U2OS (HTB-96) and HEK293T (CRL-11268) were purchased from ATCC and HeLa were authenticated using Short Tandem Repeat (STR) analysis by ATCC services (100% match). All the cells lines used were uninfected with Mycoplasma, as routinely verified using the e-Myco Mycoplasma kit from FroggaBio.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Novel strand exchange activity of the human PALB2 DNA Binding Domain and its critical role for DNA repair in cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Maria Spies as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Cynthia Wolberger as the Senior Editor. The following individual involved in review of your submission has also agreed to reveal his identity: Mark Simon Dillingham (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Your manuscript has been reviewed by three experts, who found your findings potentially interesting and important, especially the DNA strand exchange activity of the DBD of PALB2. This is an important observation because it suggests that the PALB2\'s coordination of the BRCA2, RAD51 etc. in DSB repair is not a mere hub function. Biochemical studies being paralleled by the observations in the cell are a definite strength of the paper. The reviewers. However, have identified a number of problems with the work, which need to be resolved prior to possible consideration.

Essential revisions:

Significant issues that will require additional experiments:

1\) The reported DNA (and RNA) strand exchange activity of PALB2 DBD is the main novelty of the paper. This said, it is important to distinguish the ability of PALB2 to exchange short, protein-free segments of nucleic acids from the DNA strand exchange reaction that is expected to occur at the resected DSBs and which involves longer stretches of RPA-coated ssDNA. The authors need to make this distinction clear in the Discussion. Considering the importance of PALB2-DNA interaction for DSB repair in the cell-based studies, it would be informative to test the T1 effect on the DNA strand exchange reaction involving the plasmid length substrates, such as plasmid lengths circular ssDNA and linear duplex, or a D-loop assay with supercoiled plasmid-length dsDNA. The D-loop experiment will also allow you to compare the DBD with the full-length PALB2 (you can compare these observations side by side with the published data if you don\'t have access to a full-length PALB2).

2\) It is important to determine whether the DNA strand exchange activity, which is observed to be ATP dependent, or if PALB2 DBD acts more like RAD52. The absence of the nuclease activity in the DBD preparation should be also demonstrated as even a trace amount of nuclease activity may alter the results of the FRET-based experiments.

3\) There is no evidence that the mutant proteins are properly folded or that any other intrinsic activity is maintained at wild type levels. Without further validation it is not possible to conclude that the residues directly affect DNA binding (although it is likely), nor that these mutations uncouple DNA binding from other activities of PALB2 (which is an important underlying assumption for the in vivo experiments). The authors should demonstrate that their mutant proteins are properly folded. CD spectra would be the best if the DBD possesses discernable secondary structure. The effect of the mutations on the oligomeric state of the DBD should also be probed.

4\) Figure 6: The choice of the FRET substrate with the dyes separated by 70 nucleotides may lead to an erroneous conclusion about the wrapping vs. extension of the ssDNA bound by DBD and RAD51/DBD complex. These experiments should be repeated with the substrate with the dyes positioned within the linear FRET range. It is quite unexpected for a 70-mer Cy3/Cy5-labeled substrate to exhibit an increase in the FRET signal upon RAD51 binding. This could be due to how the FRET is calculated and the fact that RAD51 enhances Cy3 fluorescence upon binding. As presented, an apparent FRET is calculated without taking into account the leakage between the channels and the difference in quantum yield of Cy3 and Cy5. While the data still support the idea of the co-complex involving RAD51 and PALB2, there is no way to deduce the DNA configuration from these data. To argue about the ssDNA configuration (ssDNA extended by RAD51 and wrapped by T1), you should repeat the experiments with a DNA substrate where the dyes are separated by no more than 25 -- 30 nt. This range is more compatible with FRET. Also, the SSB-like wrapping of the ssDNA by the T1 fragment can be revealed using the substrate with the internal placement of the dyes. For the terminally-placed dyes, one can formally argue that the FRET increase is due to the bridging of the two ends.

Significant issues that will require additional analysis/explanations

1\) Quantification of the rates and the reaction extents in Figures 5 and 7 would be highly informative.

2\) The reviewers felt that the DNA binding data are neither presented well nor sufficiently discussed. The authors should provide the equation used to quantify DNA binding. Considering the weak binding and potential cooperativity, it would be the most appropriate if an implicit Hill equation, which takes into account the difference between total and free concentration of the protein, were used. It is unclear, however, whether this was the case. The assumption of the oligomeric state used in the data fitting needs to be explicitly stated. Furthermore, the authors should discuss the evidence for cooperativity in DNA binding (if any) and report the fitting parameters.

3\) The proposed oligomeric state of the DBD should be discussed in light of the previous work (Buisson et al) that reported a dimer for the full-length PALB2. The K-A mutant binding isotherms plateau at different anisotropy values compared to the control. It is possible that the mutant protein is adopting different oligomeric states. A size exclusion chromatogram of the mutant proteins would address this concern.

4\) The protein preps of 573 or 5753-146 AAAA appears to contain degradation or contaminating proteins. How was the protein quantified? This is important consideration for the binding assays.

Suggestions for improving readability:

1\) The paper would significantly benefit from editing. For example, the Introduction reads like a long list of facts and it is unclear how these facts go together. Stating up front the rationale behind the experiment and results would make the paper much easier to follow. For example, why were \"Qualitative measurement of PALB2 interaction with ss- and dsDNA oligonucleotides of....\" analyzed? The authors should state the hypothesis.

2\) Important previous characterization data were omitted from the Introduction. For example, characterization of PALB2 from Buisson R. et al., 2010:

a\) PALB2 binds DNA substrates via two regions (explicitly list those domains).

b\) Full length PALB2 does not stimulate strand exchange reactions.

c\) Full length PALB2 promotes the strand RAD51-mediated strand exchange reaction.

3\) The rational for testing the inverse and RNA strand exchange activities should be explicitly discussed.

10.7554/eLife.44063.033

Author response

> Essential revisions:
>
> Significant issues that will require additional experiments:
>
> 1\) The reported DNA (and RNA) strand exchange activity of PALB2 DBD is the main novelty of the paper. This said, it is important to distinguish the ability of PALB2 to exchange short, protein-free segments of nucleic acids from the DNA strand exchange reaction that is expected to occur at the resected DSBs and which involves longer stretches of RPA-coated ssDNA. The authors need to make this distinction clear in the Discussion. Considering the importance of PALB2-DNA interaction for DSB repair in the cell-based studies, it would be informative to test the T1 effect on the DNA strand exchange reaction involving the plasmid length substrates, such as plasmid lengths circular ssDNA and linear duplex, or a D-loop assay with supercoiled plasmid-length dsDNA. The D-loop experiment will also allow you to compare the DBD with the full-length PALB2 (you can compare these observations side by side with the published data if you don\'t have access to a full-length PALB2).

A\) We performed a D-loop assay with ssDNA and supercoiled dsDNA plasmid. The PALB2 N-DBD fragment does not support D-loop formation with a supercoiled plasmid. Results are shown in Figure 4---figure supplement 4. We added discussion of differences in D-loop formation between N-DBD and full length PALB2.

B\) We tested RPA in strand exchange assay (new Figure 6). 0.5 μM RPA significantly inhibits N-DBD- and N-DBD/RAD51-mediated strand exchange.

> 2\) It is important to determine whether the DNA strand exchange activity, which is observed to be ATP dependent, or if PALB2 DBD acts more like RAD52.

The PALB2 strand exchange is ATP-independent. All experiments without RAD51 were performed without ATP. We now clarify this in the main text and Materials and methods.

> The absence of the nuclease activity in the DBD preparation should be also demonstrated as even a trace amount of nuclease activity may alter the results of the FRET-based experiments.

There is no measurable DNA degradation upon one hour incubation at 37°C with PALB2 in gel shifts (Figure 4---figure supplement 2). We have tested the stability of DNA substrates multiple times. We also did not observe any change in fluorescence when proteins were incubated with single-labeled Cy3 or Cy5 ([Author response image 1](#respfig1){ref-type="fig"}).

![DNA and T1 were incubated at 37C for 30 min and treated with proteinase K for 20 min and ran on Native page gel at 60 V for 30 min.\
DNA without protein were treated exactly the same and compared on rhe gel.](elife-44063-resp-fig1){#respfig1}

> 3\) There is no evidence that the mutant proteins are properly folded or that any other intrinsic activity is maintained at wild type levels. Without further validation it is not possible to conclude that the residues directly affect DNA binding (although it is likely), nor that these mutations uncouple DNA binding from other activities of PALB2 (which is an important underlying assumption for the in vivo experiments). The authors should demonstrate that their mutant proteins are properly folded. CD spectra would be the best if the DBD possesses discernable secondary structure. The effect of the mutations on the oligomeric state of the DBD should also be probed.

The mutant protein has similar solubility to that of the wild type during all purification steps. It does form tetramers (new Figure 8---figure supplement 2A). It interacts with RAD51 (new Figure 3---figure supplement 3). Therefore, protein misfolding is highly unlikely.

We do not have access to CD and cannot rule out minor conformational changes. Neither T1 nor 573 fragments were suitable for thermal denaturation assays either with Sypro Orange kit or using DSC Microcalorimeter (readily precipitated).

Overall, mutation of several basic residues to alanine is unlikely to have a significant effect on the folding of 1183 aa protein in cell. The effect is negligible compared to deletions of large domain commonly used in cellular studies of PALB2 and other proteins.

> 4\) Figure 6: The choice of the FRET substrate with the dyes separated by 70 nucleotides may lead to an erroneous conclusion about the wrapping vs. extension of the ssDNA bound by DBD and RAD51/DBD complex. These experiments should be repeated with the substrate with the dyes positioned within the linear FRET range. It is quite unexpected for a 70-mer Cy3/Cy5-labeled substrate to exhibit an increase in the FRET signal upon RAD51 binding. This could be due to how the FRET is calculated and the fact that RAD51 enhances Cy3 fluorescence upon binding. As presented, an apparent FRET is calculated without taking into account the leakage between the channels and the difference in quantum yield of Cy3 and Cy5. While the data still support the idea of the co-complex involving RAD51 and PALB2, there is no way to deduce the DNA configuration from these data. To argue about the ssDNA configuration (ssDNA extended by RAD51 and wrapped by T1), you should repeat the experiments with a DNA substrate where the dyes are separated by no more than 25 -- 30 nt. This range is more compatible with FRET. Also, the SSB-like wrapping of the ssDNA by the T1 fragment can be revealed using the substrate with the internal placement of the dyes. For the terminally-placed dyes, one can formally argue that the FRET increase is due to the bridging of the two ends.

Note, that the increase of FRET upon RAD51 binding was observed in the absence of ATP, and FRET decreases when ATP is added. Nevertheless, we agree that this experiment is inconclusive and requires additional controls. We decided to remove this experiment (former Figure 6) from main text.

In the revised version, we show only FRET experiments with 40- and 70-nt ssDNA in Figure 8---figure supplement 2. The leakage between channels was measured and incorporated into the FRET estimate as described now in Materials and methods.

> Significant issues that will require additional analysis/explanations
>
> 1\) Quantification of the rates and the reaction extents in Figures 5 and 7 would be highly informative. Figure 5D may be represented with units/sec for the initial phase.

We found that for current data, the rates do not provide any additional information. We calculated initial rates for the strand exchange experiments and the rates for the new Figure 7 ([Author response image 2](#respfig2){ref-type="fig"}). It will not provide valuable information for comparison with similar activity of RAD52 (Mazina et al., 2017), where all data are reported in product% and not with rate values. However, we did add comparisons with apparent rates in our and the referred paper in the Discussion.

![Table with initial rates (bottom) calculated for reactions in Figure 7.](elife-44063-resp-fig2){#respfig2}

We agree with the reviewers that proper quantification is necessary for mechanistic insight into PALB2 DNA-binding and strand-exchange. However, comprehensive mechanistic studies of this system will require a significant number of additional experiments and are beyond the scope of this manuscript.

> 2\) The reviewers felt that the DNA binding data are neither presented well nor sufficiently discussed. The authors should provide the equation used to quantify DNA binding. Considering the weak binding and potential cooperativity, it would be the most appropriate if an implicit Hill equation, which takes into account the difference between total and free concentration of the protein, were used. It is unclear, however, whether this was the case.

Thank you for pointing to this important gap in initial presentation. We described DNA binding in more details in Materials and methods, included Hill coefficient measurements and tables with binding parameters. Hill coefficient was closure to 1, suggesting noncooperative binding, except T1 binding to ds49, which may be an artifact of the short domain, as it is not the case for 573 fragment.

The effect of protein depletion is not encountered (accordingly to recommendations for FP assay in Prism). We referred it as an apparent equilibrium dissociation constant. We have the changed main text and Materials and methods accordingly.

> The assumption of the oligomeric state used in the data fitting needs to be explicitly stated. Furthermore, the authors should discuss the evidence for cooperativity in DNA binding (if any) and report the fitting parameters.

We did not account for oligomeric state in DNA-binding fitting. As mentioned above, we do not observe significant cooperativity. Instead, we observed higher affinity towards longer ssDNA substrates, suggesting interaction of long ssDNA with multiple sites. We speculate that multiple binding sites can be provided by an oligomeric T1 structure observed in SEC experiments. This situation resembles ssDNA binding by SSB. We are currently isolating mutants affecting T1 oligomerization, but this will take additional time to study.

> 3\) The proposed oligomeric state of the DBD should be discussed in light of the previous work (Buisson et al.) that reported a dimer for the full-length PALB2.

We have added corresponding discussion.

> The K-A mutant binding isotherms plateau at different anisotropy values compared to the control. It is possible that the mutant protein is adopting different oligomeric states. A size exclusion chromatogram of the mutant proteins would address this concern.

The mutant also forms tetramer. Due to weak binding, anisotropy isotherms do not reach plateaus in case of mutants, explaining their low anisotropy values. Overall, the T1 truncation and its mutants are relatively unstable under the binding conditions. We are trying to isolate a more stable truncation suitable for future quantitative mechanistic studies of PALB2 DNA interaction and strand annealing.

> 4\) The protein preps of 573 or 5753-146 AAAA appears to contain degradation or contaminating proteins. How was the protein quantified? This is important consideration for the binding assays.

We present data for newly purified proteins. While modified purification methods with an additional chromatography step yield cleaner products, we cannot completely eliminate minor contamination by a likely degradation product. New preps have similar binding parameters. Such minor contamination should not affect comparative analysis of wild type and mutant proteins identically purified.

> Suggestions for improving readability:
>
> 1\) The paper would significantly benefit from editing. For example, the Introduction reads like a long list of facts and it is unclear how these facts go together. Stating up front the rationale behind the experiment and results would make the paper much easier to follow. For example, why were \"Qualitative measurement of PALB2 interaction with ss- and dsDNA oligonucleotides of....\" analyzed? The authors should state the hypothesis.

This is an important point and we have tried to improve our presentation. We mentioned controversial results from previous publications and added additional description of the significance of DNA binding for the function of recombination mediator proteins.

> 2\) Important previous characterization data were omitted from the Introduction. For example, characterization of PALB2 from Buisson R. et al., 2010:
>
> a\) PALB2 binds DNA substrates via two regions (explicitly list those domains).

Added.

> b\) Full length PALB2 does not stimulate strand exchange reactions.

We added discussion of this fact (subsection "PALB2 stimulates RAD51-mediated strand exchange and promotes a similar reaction without RAD51").

> c\) Full length PALB2 promotes the strand RAD51-mediated strand exchange reaction.

We added discussion of this fact (subsection "PALB2 stimulates RAD51-mediated strand exchange and promotes a similar reaction without RAD51").

> 3\) The rational for testing the inverse and RNA strand exchange activities should be explicitly discussed.

See subsection "PALB2 stimulates an inverse strand exchange and can use an RNA substrate".

[^1]: John T Milliken Department of Medicine, Division of Pulmonology and Critical Care Medicine, Washington University School of Medicine, Saint Louis, United States.
